Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
19 NC counties are under alert, including Wake, Durham, Orange, Nash, and Franklin counties.
Program
On WRAL at 5: Multiple reports of flooding and storm damage. Where weâre seeing trouble spots in the WRAL Storm Tracker
Program
On WRAL at 6: WRAL Investigates why a school took nearly two years to report alleged abuse to law enforcement and parents.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
27.05
+1.11 (+4.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
July 07, 2022
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ:
Via
Benzinga
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
July 05, 2022
The FDA's advisors recently backed Pfizer's Covid shot for young children.
Via
Investor's Business Daily
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
June 17, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 08, 2022
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...
Via
Benzinga
Expert Ratings For Beam Therapeutics
January 10, 2022
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock?
January 13, 2022
How the pandemic continued a transformation Pfizer says began years ago.
Via
Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
January 10, 2022
Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ...
Via
Benzinga
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:
Via
Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
Two big biotechs and one smaller one that could be winners over the long term.
Via
The Motley Fool
Being First Is Not Enough For Crispr Therapeutics
November 15, 2021
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.
Via
InvestorPlace
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
November 12, 2021
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
November 09, 2021
Can this high-flying gene-editing stock keep on climbing for new investors?
Via
The Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
November 08, 2021
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a...
Via
Benzinga
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
October 19, 2021
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:
Via
Benzinga
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
October 15, 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Via
The Motley Fool
Exposures
Product Safety
Beam Therapeutics Stock Flashes Renewed Technical Strength
October 12, 2021
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.
Via
Investor's Business Daily
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
September 27, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce...
Via
Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
September 23, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ...
Via
Benzinga
Beam Therapeutics's Return On Capital Employed Insights
September 22, 2021
According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company...
Via
Benzinga
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
September 15, 2021
The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.